vs
Side-by-side financial comparison of PATHWARD FINANCIAL, INC. (CASH) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
PATHWARD FINANCIAL, INC. is the larger business by last-quarter revenue ($173.1M vs $86.8M, roughly 2.0× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -0.2%). PATHWARD FINANCIAL, INC. produced more free cash flow last quarter ($104.1M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -18.0%).
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CASH vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $173.1M | $86.8M |
| Net Profit | $35.2M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 24.6% | -84.7% |
| Net Margin | 20.3% | — |
| Revenue YoY | -0.2% | 17.7% |
| Net Profit YoY | 11.9% | — |
| EPS (diluted) | $1.57 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $173.1M | $86.8M | ||
| Q3 25 | $186.7M | $67.5M | ||
| Q2 25 | $195.8M | $60.0M | ||
| Q1 25 | $274.8M | $49.3M | ||
| Q4 24 | $182.6M | $73.7M | ||
| Q3 24 | $179.5M | $58.6M | ||
| Q2 24 | $188.6M | $31.1M | ||
| Q1 24 | $257.6M | $715.0K |
| Q4 25 | $35.2M | — | ||
| Q3 25 | $38.8M | $-91.3M | ||
| Q2 25 | $42.1M | $-111.7M | ||
| Q1 25 | $75.0M | $-116.2M | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $33.5M | $-83.5M | ||
| Q2 24 | $44.9M | $-97.1M | ||
| Q1 24 | $69.9M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 24.6% | -84.7% | ||
| Q3 25 | 25.9% | -140.7% | ||
| Q2 25 | 24.1% | -189.8% | ||
| Q1 25 | 33.2% | -245.8% | ||
| Q4 24 | 19.8% | -117.5% | ||
| Q3 24 | 20.9% | -152.1% | ||
| Q2 24 | 27.1% | -327.6% | ||
| Q1 24 | 33.8% | -16464.6% |
| Q4 25 | 20.3% | — | ||
| Q3 25 | 20.8% | -135.3% | ||
| Q2 25 | 21.5% | -186.2% | ||
| Q1 25 | 27.3% | -235.5% | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 18.7% | -142.7% | ||
| Q2 24 | 23.8% | -312.2% | ||
| Q1 24 | 27.1% | -15800.8% |
| Q4 25 | $1.57 | — | ||
| Q3 25 | $1.69 | — | ||
| Q2 25 | $1.81 | $-0.33 | ||
| Q1 25 | $3.14 | $-0.36 | ||
| Q4 24 | $1.23 | $-0.24 | ||
| Q3 24 | $1.34 | $-0.28 | ||
| Q2 24 | $1.78 | $-0.34 | ||
| Q1 24 | $2.74 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $331.2M | $297.0M |
| Total DebtLower is stronger | $33.5M | — |
| Stockholders' EquityBook value | $854.5M | $698.6M |
| Total Assets | $7.6B | $913.2M |
| Debt / EquityLower = less leverage | 0.04× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $331.2M | $297.0M | ||
| Q3 25 | $120.6M | $300.8M | ||
| Q2 25 | $258.3M | $301.2M | ||
| Q1 25 | $254.2M | $359.7M | ||
| Q4 24 | $597.4M | $323.8M | ||
| Q3 24 | $158.3M | $397.5M | ||
| Q2 24 | $298.9M | $412.5M | ||
| Q1 24 | $347.9M | $356.2M |
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.5M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $33.4M | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $33.4M | — |
| Q4 25 | $854.5M | $698.6M | ||
| Q3 25 | $858.0M | $702.3M | ||
| Q2 25 | $819.0M | $698.5M | ||
| Q1 25 | $814.7M | $767.9M | ||
| Q4 24 | $758.3M | $710.4M | ||
| Q3 24 | $822.5M | $773.5M | ||
| Q2 24 | $748.4M | $768.5M | ||
| Q1 24 | $719.5M | $680.0M |
| Q4 25 | $7.6B | $913.2M | ||
| Q3 25 | $7.2B | $904.9M | ||
| Q2 25 | $7.2B | $907.4M | ||
| Q1 25 | $7.0B | $966.7M | ||
| Q4 24 | $7.6B | $910.4M | ||
| Q3 24 | $7.5B | $991.1M | ||
| Q2 24 | $7.5B | $964.3M | ||
| Q1 24 | $7.4B | $869.8M |
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.05× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.3M | $-52.6M |
| Free Cash FlowOCF − Capex | $104.1M | $-61.9M |
| FCF MarginFCF / Revenue | 60.1% | -71.3% |
| Capex IntensityCapex / Revenue | 2.4% | 10.7% |
| Cash ConversionOCF / Net Profit | 3.08× | — |
| TTM Free Cash FlowTrailing 4 quarters | $616.8M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.3M | $-52.6M | ||
| Q3 25 | $303.7M | $-78.7M | ||
| Q2 25 | $30.4M | $-67.4M | ||
| Q1 25 | $188.3M | $-103.7M | ||
| Q4 24 | $-71.7M | $-73.3M | ||
| Q3 24 | $143.1M | $-59.0M | ||
| Q2 24 | $113.2M | $-98.4M | ||
| Q1 24 | $203.0M | $-122.3M |
| Q4 25 | $104.1M | $-61.9M | ||
| Q3 25 | $300.3M | $-89.5M | ||
| Q2 25 | $27.7M | $-74.9M | ||
| Q1 25 | $184.7M | $-109.9M | ||
| Q4 24 | $-73.8M | $-77.5M | ||
| Q3 24 | $138.8M | $-61.3M | ||
| Q2 24 | $111.0M | $-98.9M | ||
| Q1 24 | $201.3M | $-126.5M |
| Q4 25 | 60.1% | -71.3% | ||
| Q3 25 | 160.9% | -132.7% | ||
| Q2 25 | 14.1% | -124.9% | ||
| Q1 25 | 67.2% | -222.8% | ||
| Q4 24 | -40.4% | -105.1% | ||
| Q3 24 | 77.3% | -104.6% | ||
| Q2 24 | 58.8% | -317.9% | ||
| Q1 24 | 78.1% | -17685.3% |
| Q4 25 | 2.4% | 10.7% | ||
| Q3 25 | 1.8% | 16.1% | ||
| Q2 25 | 1.4% | 12.4% | ||
| Q1 25 | 1.3% | 12.6% | ||
| Q4 24 | 1.1% | 5.7% | ||
| Q3 24 | 2.4% | 3.9% | ||
| Q2 24 | 1.2% | 1.4% | ||
| Q1 24 | 0.7% | 583.4% |
| Q4 25 | 3.08× | — | ||
| Q3 25 | 7.83× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 2.51× | — | ||
| Q4 24 | -2.39× | — | ||
| Q3 24 | 4.27× | — | ||
| Q2 24 | 2.52× | — | ||
| Q1 24 | 2.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CASH
| Consumer | $103.0M | 59% |
| Payment Card And Deposit Fees | $30.1M | 17% |
| Other | $24.2M | 14% |
| Rental Income | $11.6M | 7% |
| Commercial | $4.2M | 2% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
